Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine CandidateAug 14, 2020 at 1:07 AM EDT http://ir.novavax.com/news-releases/news-release-details/novavax-and-uk-government-announce-collaboration-and-purchase
13 AUGUST 2020Brazil’s Parana state to produce Russia’s Covid-19 vaccinehttps://www.pharmaceutical-technology.com/news/brazil-parana-state-russia-vaccine/
Putin claims Russia has developed the first coronavirus vaccineAug. 11, 2020 5:24 AM ET|About: Pfizer Inc. (PFE)|By: Yoel Minkoff, SA News Editor https://seekingalpha.com/news/3603880-putin-claims-russia-developed-first-coronavirus-vaccine
Sorrento adds to COVID-19-stoked rally, shares up 24% Aug. 10, 2020 1:56 PM ET|About: Sorrento Therapeutics,... (SRNE)|By: Douglas W. House, SA News Editor Sorrento Therapeutics (SRNE +23.6%) is adding to its recent breakout on almost double normal volume. Shares have jumped 159% since Wednesday, July 24, when it announced that it planned to acquire COVID-19 therapy developer SmartPharm Therapeutics. The following Monday, July 29, it announced that it in-licensed rights to a rapid test that detects the presence of the SARS-CoV-2 virus in saliva in as little as 30 minutes.On Friday, May 15, shares rocketed 158% after the company announced a "cure" for COVID-19. Shares quickly retraced on questions about the veracity of its claim, bottoming at $3.82 on June 4. Investors appeared to have brushed off such concerns since shares are up five-fold since then.Chairman, CEO and President Henry Li, Ph.D. is, no doubt, pleased with the share appreciation. Last week, the board authorized a 10-year performance award for him based solely on the market cap of the company. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company's market cap reaches $5B. The 10th and last tranche vests if the company's value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B. https://seekingalpha.com/news/3603544-sorrento-adds-to-covidminus-19-stoked-rally-shares-up-24?utm_medium=email&utm_source=seeking_alpha&mail_subject=srne-sorrento-adds-to-covid-19-stoked-rally-shares-up-24&utm_campaign=rta-stock-news&utm_content=link-3
Pfizer to manufacture COVID-19 med remdesivirAug. 7, 2020 8:10 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor https://seekingalpha.com/news/3602826-pfizer-to-manufacture-covidminus-19-med-remdesivir?utm_medium=email&utm_source=seeking_alpha&mail_subject=gild-pfe-pfizer-to-manufacture-covid-19-med-remdesivir&utm_campaign=rta-stock-news&utm_content=link-3
Alguna experiencia por aqui, con este indicador ?Fibonacci Time ZonesWhat are Fibonacci Time Zones?KEY TAKEAWAYSFibonacci time zones are vertical lines that represent potential areas where a swing high, low, or reversal could occur.Fibonacci time zones may not indicate exact reversal points. They are time-based areas to be aware of.Fibonacci time zones only indicate potential areas of importance related to time. No regard is given to price. The zone could mark a minor high or low, or a significant high or low.Fibonacci time zones are based on the Fibonacci number sequence which gives us the Golden Ratio. The ratio is found throughout nature and architecture.https://www.investopedia.com/terms/f/fibonaccitimezones.asp#:~:text=Fibonacci%20time%20zones%20are%20a,high%2C%20low%2C%20or%20reversal.
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales https://investors.dynavax.com/news-releases/news-release-details/trisalus-life-sciences-acquires-dynavaxs-sd-101-oncology-program
Pricing Covid-19 vaccines too high could backfire on big pharmaceutical companies.. I don’t want to single out Moderna here. It doesn’t have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer NSE 2.30% Inc.’s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were “fanatic and radical.” (AstraZeneca NSE 1.51% PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines, Read more at:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pricing-covid-19-vaccines-too-high-could-backfire-on-big-pharmaceutical-companies/articleshow/77325474.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst ..